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Diagnostics are a cornerstone of the practice of infectious diseases. However, various limitations frequently lead to unmet clinical 
needs. In most other domains, diagnostics focus on narrowly defined questions, provide readily interpretable answers, and use true 
gold standards for development. In contrast, infectious diseases diagnostics must contend with scores of potential pathogens, dozens 
of clinical syndromes, emerging pathogens, rapid evolution of existing pathogens and their associated resistance mechanisms, and 
the absence of gold standards in many situations. In spite of these challenges, the importance and value of diagnostics cannot be un-
derestimated. Therefore, the Antibacterial Resistance Leadership Group has identified diagnostics as 1 of 4 major areas of emphasis. 
Herein, we provide an overview of that development, highlighting several examples where innovation in study design, content, and 
execution is advancing the field of infectious diseases diagnostics.
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The health and economic consequences of increasing antibac-
terial resistance have led to numerous calls for action. A mean-
ingful impact on the resistance problem cannot come from 
just one domain. Rather, we require advances that span multi-
ple domains, including limiting unnecessary antibiotic use in 
human and animal populations, developing new antimicrobial 
agents, and improving the state of infectious diseases diagnos-
tics. Anticipating the important role that diagnostics play in 
combatting resistance, the Antibacterial Resistance Leadership 
Group (ARLG) has identified diagnostics as 1 of 4 primary 
emphasis areas. Specifically, the ARLG has prioritized the devel-
opment and evaluation of diagnostic tests that are designed to 
rapidly detect or exclude bacterial infection, accurately identify 
bacterial pathogens, and/or inform selection of antibacterial 
agents (Table 1) [1–5].
It is clear that faster, better, and less-expensive versions of 
existing diagnostics represent advances. In addition, new tech-
nologies and strategies have the potential to transform infec-
tious diseases diagnostics. However, when developing a new 
diagnostic, both cost and practical aspects of implementation 
have to be taken into consideration. For example, rapid blood 
culture identification of pathogens has the most meaningful 
impact on patient outcomes only when paired with appropri-
ately delivered clinical decision-making guidance [1].
In addition to the standard approach of pathogen identifi-
cation, diagnostics based on host response can provide useful 
information. For example, procalcitonin, a biomarker that cor-
relates with bacterial infection, may be helpful to guide antibac-
terial use. Given the richness and complexity of host responses 
to infection, in some cases, single biomarkers (even very good 
ones) cannot be expected to capture all useful diagnostic infor-
mation. As a proof of concept, the ARLG has therefore sup-
ported the development of host gene expression signatures as 
a tool for the differentiation between viral and bacterial infec-
tions. Although these and the other ARLG diagnostic programs 
are important advances, they represent only the beginning. The 
ARLG remains steadfastly committed to exploring, developing, 
and promoting the use of diagnostics in combating antibacterial 
resistance.
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ADVANCING DIAGNOSTIC DEVELOPMENT USING A 
NOVEL STUDY DESIGN CALLED MASTERMIND
Obtaining regulatory approval for a new diagnostic test can 
be challenging due to a lack of an appropriate reference stand-
ard, limited access to good-quality, well-characterized clinical 
specimens, and/or costs. To address this, the Diagnostics and 
Devices Committee collaborated with the ARLG Statistical 
and Data Management [7] and Leadership and Operations 
[8] centers in the development of a novel study design called
MASTERMIND (Master Protocol for Evaluating Multiple
Infection Diagnostics), which facilitates what might have
been unfeasible using conventional methods [6, 9, 10]. The
MASTERMIND concept uses a single patient’s sample(s) to
evaluate multiple tests, providing efficiencies of scale for
simultaneous or successive investigations. For a detailed
description of the MASTERMIND scheme, see “Viewpoint:
MASTERMIND—Bringing Microbial Diagnostics to the
Clinic” in a recent issue of Clinical Infectious Diseases [6].
The first MASTERMIND study—MASTERMIND-CT/NG—
involves additional collaboration with the Special Populations 
Special Emphasis Panel and is designed to validate multiple 
companies’ nucleic acid amplification tests (NAATs) for rec-
tal and oropharyngeal Chlamydia trachomatis and Neisseria 
gonorrhoeae. Despite the US Centers for Disease Control and 
Prevention’s recommendation to use NAATs for this diagnosis 
[11], there are currently no US Food and Drug Administration 
(FDA)–cleared assays for extragenital sites. The involved com-
panies already have FDA-cleared NAATs for genital C.  tra-
chomatis and N. gonorrhoeae, minimizing the technical hurdle 
for additional anatomic site testing. This study will return prod-
uct performance data to the respective companies in support 
of FDA clearance for extragenital C. trachomatis and N. gonor-
rhoeae detection (ClinicalTrials.gov identifier: NCT02870101). 
In order to initiate this precedent-setting diagnostics study, the 
ARLG used the expertise of its infectious diseases physicians, 
clinical microbiologists, and statisticians; collaborated with 
industry; and sought input from governmental agencies.
Beyond extragenital gonorrhea and C.  trachomatis, future 
MASTERMIND-type studies to target a number of organisms 
in a variety of specimen types are being discussed. Several 
challenges have arisen while developing this concept, includ-
ing defining a reference standard when none exists, achieving 
Table 1. List of Antibacterial Resistance Leadership Group Diagnostic Studies
Study Name Description Status
BCID: Randomized Trial of Blood Culture  
Pathogen Identification using the  
FilmArray Blood Culture Identification Panel
Randomized controlled trial to evaluate an effect of rapid blood 
culture diagnostic on outcomes
Complete [1]
CEP-CON: Cepheid Control Collection of oral and rectal swabs for development of an assay for 
Neisseria gonorrhoeae and Chlamydia trachomatis
Ongoing
CEP-CRO: Cepheid-Diagnostic for  
Carbapenem Resistant Organisms
Collection of endotracheal aspirate and bronchoalveolar lavage fluid 
matrix for development of an assay detecting carbapenem-resis-
tant organisms
Complete
CEP-VAP: Cepheid-Diagnostic for Ventilator 
Associated Pneumonia
Collection of bronchoalveolar lavage fluid matrix for development of  
pathogen-detection assays
Complete
Diagnostics Working Group Collaboration of industry partners, Antibacterial Resistance 
Leadership Group, and regulators to discuss diagnostic chal-
lenges and solutions
Ongoing
MASTERMIND-CT/NG: Master Protocol for 
Evaluating Multiple Infection Diagnostics–
Chlamydia trachomatis/Neisseria gonorrhoeae
MASTERMIND study evaluating multiple companies’ diagnostics for 
extragenital C. trachomatis and gonorrhea infections
Protocol development;  
enrollment preparation [6]
PRIMERS I–IV: Platforms for Rapid  
Identification of MDR-Gram negative  
Bacteria and Evaluation of Resistance  
Studies I–IV
Development of platforms to rapidly identify antibiotic-resistant 
gram-negative bacteria:
• PRIMERS I: Evaluation of 72 Enterobacteriaceae isolates on 4 
RMD platforms
• PRIMERS II: Evaluation of 196 Enterobacteriaceae isolates on 2 
RMD platforms
• PRIMERS III: Evaluation of 200 Acinetobacter isolates on 2 RMD 
platforms
• PRIMERS IV: Evaluation of 197 Pseudomonas aeruginosa isolates 





RADICAL: Rapid Diagnostics in Categorizing  
Acute Lung Infections
Development and validation of host gene expression classifiers 
of bacterial, viral, or noninfectious illness in patients with acute 
respiratory illness
Enrollment complete;
 platform development and 
validation
RAPIDS-GN: Rapid Diagnostics for Gram- 
Negative Bacteria in Blood
Determination of the effect of rapid antimicrobial susceptibility test-
ing on outcomes in patients with gram-negative infections
Protocol development
TRAP-LRTI: Use of Procalcitonin Testing to  
Direct Antibiotic Use in Lower Respiratory  
Tract Infections
Randomized, placebo-controlled trial of azithromycin vs placebo  
in patients with lower respiratory tract infection and a low  
procalcitonin
Protocol development
Abbreviations: MDR, multidrug resistant; RMD, rapid molecular diagnostic.
consensus among participants and regulatory agencies regard-
ing protocol design, reconciling competition and collaboration, 
and simultaneously evaluating multiple testing platforms from 
an operational perspective. Despite these challenges, the ARLG 
sees a prominent future for the MASTERMIND concept, par-
ticularly where diagnostics trials become cost and resource 
prohibitive. Our success in designing the first MASTERMIND 
study, MASTERMIND-CT/NG, demonstrates the feasibility of 
an alternative pathway for diagnostics development.
RAPID DIAGNOSIS OF BLOODSTREAM INFECTION
Novel molecular diagnostic tests that allow rapid detection of 
pathogens and drug resistance can in theory facilitate timely 
administration of “pathogen-directed” antimicrobial therapy 
[12–16]. However, whether these, often costly, rapid diag-
nostics actually improve patient-centered clinical outcomes, 
reduce healthcare costs, or improve antibiotic use is unknown. 
Thoughtful implementation strategies for rapid molecular diag-
nostics are essential to maximize the clinical impact of these 
tests. In particular, it is unclear how to most effectively com-
municate rapid test results to providers in order to influence 
clinical decision making in real time.
The partially ARLG-funded Randomized Trial of Blood 
Culture Pathogen Identification using the FilmArray Blood 
Culture Identification Panel study was a single-center, prospective, 
randomized, controlled, 3-arm trial that evaluated the clinical and 
economic outcomes associated with use of the FilmArray Blood 
Culture Identification (BCID) Panel—an FDA-approved rapid 
diagnostic that can identify multiple bacteria, fungi, and common 
antimicrobial-resistance genes (mecA, vanA/B, blaKPC) in about 
1 hour following organism growth in a blood culture bottle [1]. 
The trial compared standard-of-care testing and reporting with 2 
strategies to guide healthcare providers’ responses to the rapid test 
results: electronic comments with treatment guidance alone or 
with active oversight by an antimicrobial stewardship team.
Patients with Gram stain–positive blood cultures under-
went stratified randomization to 1 of 3 groups: a control group 
with standard culture and antimicrobial susceptibility testing; 
BCID testing with treatment guidance included in the micro-
biology result report; or BCID testing with treatment guidance 
included in the microbiology result report plus real-time audit 
and feedback by antimicrobial stewardship interventionists. 
Pathogen identification was 21 hours faster in the BCID groups 
compared with the control group. Study groups had significant 
differences in antibiotic use, with both BCID arms having less 
broad-spectrum antibiotic use, more narrow-spectrum antibi-
otic use, less treatment of contaminants, and faster antibiotic 
escalation, compared with the control group. However, faster 
antibiotic deescalation occurred only in the group using BCID 
plus stewardship. Groups did not differ in length of stay, hospi-
talization costs, mortality, adverse drug events, or Clostridium 
difficile infection rates, although the study was not powered to 
detect these secondary outcomes.
The BCID trial was the first randomized, controlled trial 
to evaluate a rapid blood culture diagnostic in terms of clini-
cal outcomes and implementation strategies. Results from the 
study suggest that rapid diagnostics implemented with auto-
mated clinical decision support systems can optimize treatment 
of bloodstream infections. However, clinical impact will be 
maximized when rapid diagnostics are used together with anti-
microbial stewardship interventions. Future randomized, con-
trolled trials of novel diagnostics and implementation strategies 
are planned. Other ARLG antimicrobial stewardship efforts are 
described elsewhere [17].
MOLECULAR DIAGNOSTIC PLATFORMS TO DETECT 
RESISTANCE PHENOTYPES
Conventional resistance testing relies on phenotypic antimi-
crobial susceptibility testing—growth of the organism in the 
presence of an antibiotic. However, genotypic testing is faster 
and therefore increasingly used. Such tests determine whether 
a resistance gene is present or absent. If present, one assumes 
the organism is resistant. The clinical utility of such genotypic, 
molecular tests to predict antibiotic susceptibility and resist-
ance is straightforward when the phenotype is determined by 
a single gene (eg, mecA, vanA/B). However, the feasibility of 
this approach is less clear when the phenotype is determined 
by multiple genes, mutations, or combinations thereof. The 
PRIMERS (Platforms for Rapid Identification of MDR-Gram 
Negative Bacteria and Evaluation of Resistance Studies) series of 
studies, a collaboration with the ARLG Laboratory Center [18], 
focused on evaluating the performance of rapid molecular diag-
nostic platforms in identifying susceptibility and resistance to 
β-lactam antibiotics in Enterobacteriaceae (PRIMERS I and II) 
[2], Acinetobacter species (PRIMERS III) [3], and Pseudomonas 
aeruginosa (PRIMERS IV) [5]. Each platform evaluated iso-
lates for the presence or absence of specific β-lactamase genes 
associated with resistance. Platform results were interpreted as 
“resistant” if targets were present and “susceptible” if not. Each 
platform was compared to the reference standard of minimum 
inhibitory concentrations (MICs) determined using Clinical 
and Laboratory Standards Institute standards.
Correct interpretation of molecular test results could 
not be achieved by simply reporting an isolate as suscepti-
ble or resistant. Therefore, several statistics were generated 
for the PRIMERS projects by the ARLG Statistical and Data 
Management Center [7], including the discrimination sum-
mary (DIM SUM) plot. DIM SUM can be interpreted as the 
probability that the platform result indicates resistance or sus-
ceptibility when the corresponding MIC is interpreted as resist-
ant or susceptible. Also calculated were susceptibility/resistance 
predictive values (SPVs/RPVs), which are the probability that 
an MIC result will indicate susceptibility/resistance based on 
the platform result. SPV and RPV were shown to depend on 
the prevalence of susceptibility, which varies geographically and 
temporally. Consequently, SPVs/RPVs were plotted as a func-
tion of susceptibility prevalence for use with local antibiograms 
and additional information [7].
A NOVEL DIAGNOSTIC PLATFORM BASED ON HOST 
RESPONSE TO INFECTION
Inappropriate prescribing of antibacterial agents for viral 
acute respiratory illness (ARI) contributes to increased 
healthcare costs and unnecessary drug-related adverse 
effects, and it is a primary driver of antimicrobial resistance 
[19–22]. Most such antimicrobial use is in the outpatient set-
ting, where the tools to identify those in need of antibacterial 
treatment are lacking [23–25]. An accessible, rapid, accurate, 
near-patient diagnostic that discriminates viral from bac-
terial infection has the potential to reduce inappropriate 
antimicrobial prescribing and stem the rising rates of anti-
bacterial resistance.
The R ADICAL ( Rapid D iagnostics i n C ategorizing Acute 
Lung Infections) study is predicated on the idea that exter-
nal stressors induce a compensatory host response. Those 
responses can be detected and quantified i n a  v ariety o f 
molecular schemes, such as the transcriptome, metabolome, 
and proteome settings, among others (Figure  1). Moreover, 
the host response to a particular stress is stereotypical. This 
allows machine-learning techniques, such as sparse logistic 
regression, to define s ignatures i nduced b y v iral A RI, b ac-
terial ARI, or noninfectious illness. The A RLG h as c apital-
ized on nearly 10 years of prior work by the RADICAL team, 
which has defined host response signatures with the goal of 
translating them to clinically relevant platforms (Figure  2) 
[26–31].
In 2014, RADICAL began to validate host response sig-
natures to viral ARI, bacterial ARI, and noninfectious illness 
[29]. RADICAL enrollment is intentionally broad, focusing 
on patients with ARI of bacterial, viral, or noninfectious eti-
ologies in whom diagnostic testing or antibacterial therapy is 
being considered. Upon enrollment, peripheral whole blood 
is collected and banked for later gene expression analysis. The 
program also supports collaboration with industry to develop 
clinically useful tests for these host response signatures. The 
ideal test is envisioned as a simple sample-to-answer product, 
available at or near the point of care, and one that is rapid and 
affordable. Th e RA DICAL pr oject ai ms to  validate th e ho st 
response as a diagnostic strategy, as well as any novel platform 
that arises from its development.
Among the greatest challenges in developing a 
bacterial vs a viral test is the lack of a gold standard. No 
single diag-nostic test has proven sufficiently accurate 
for determin-ing if a patient’s symptoms are due to an 
infectious process 
and, if so, whether it is bacterial or viral. Therefore, the 
RADICAL team—in collaboration with the ARLG Steering 
Committee, Laboratory Center, and Diagnostics and Devices 
Figure 1. Overview of the development process for a host diagnostic biomarker. 
Beginning with a population that is dichotomized by susceptibility, diagnosis, 
or prognosis, biological samples are acquired. Omic measurements are run on 
these samples, which generates large quantities of data. Dimension reduction 
and statistical analyses generate a classifier or signature that distinguishes the 
desired characteristic from the original population. The classifier is then validated 
against a different population to test its generalizability. (Used with permission 
from Yang WE, et al. Host-based diagnostics for detection and prognosis of infec-
tious diseases. In: Sails A, Tang YW, eds. Methods in Microbiology. Elsevier Ltd, 
2015;42[13]:465–500.).
Committee—has developed a reference standard to use in 
the validation of a bacterial vs a viral diagnostic assay. When 
multiple tests are necessary for adequate classification, yet no 
predefined composite of tests is considered sufficiently accu-
rate, an expert panel diagnosis is considered the best available 
reference standard [32, 33]. The inherent complexity of this 
syndrome not only requires classification of infection but also 
the likely etiologic agent, significance of multiple pathogens, 
and likelihood that an identified pathogen is causal. Such a 
scheme standardizes reporting of expert panel adjudications 
and offers levels of confidence associated with that classifi-
cation. This in turn helps align the reference standard with 
recommended standards for reporting studies of diagnostic 
accuracy [34, 35].
In the next phases of the RADICAL project, enrollment will 
include pediatric populations and additional geographic areas. 
Platform development and translation will continue, includ-
ing analytical validation, hopefully followed by regulatory 
clearance. If successful, the RADICAL project will introduce a 
completely new diagnostic strategy that is more accurate than 
current testing, with results available at the time of clinical deci-
sion making.
PROCALCITONIN-DIRECTED TREATMENT OF LOWER 
RESPIRATORY TRACT INFECTION
Similar to the RADICAL study, which focuses on ARI, 
the TRAP-LRTI (Targeted Reduction of Antibiotics using 
Procalcitonin in Lower Respiratory Tract Infection) study, 
a collaboration with the ARLG Stewardship and Infection 
Control Committee [17], proposes to evaluate a biomarker 
approach for the management of lower respiratory tract infec-
tion (LRTI). Procalcitonin was first described in the setting 
of sepsis, where concentrations were noted to be increased 
compared with noninfectious conditions [36]. Moreover, pro-
calcitonin has been used to distinguish bacterial from viral 
infections based on the observation that interferon gamma 
production induced by viral infections inhibits procalcitonin 
production [37]. As a result, in several European studies, pro-
calcitonin-guided management of ARI has been used to with-
hold antibiotics or shorten the duration of antibiotic therapy, 
without adversely affecting outcomes [38–41]. Despite this 
body of research, the FDA-approved indication for procalci-
tonin use focuses on sepsis. Specifically, procalcitonin is to 
be used in conjunction with other laboratory findings and 
clinical assessments to aid in risk assessment of critically ill 
patients on their first day of intensive care unit admission 
for progression to severe sepsis and septic shock. In collab-
oration with a diagnostic manufacturer and in consultation 
with the FDA, the ARLG has proposed TRAP-LRTI to expand 
the indication for use. This multicenter, double-blind, rand-
omized, placebo-controlled trial will enroll adults present-
ing to the emergency department and outpatient clinics with 
LRTI. Patients with a procalcitonin concentration <0.1 ng/
mL will be randomized to receive placebo or standard-course 
azithromycin. The primary outcome is to compare the efficacy 
of azithromycin vs placebo on study day 5 using a noninfe-
riority approach. The hypothesis is that clinical outcomes of 
patients with a procalcitonin concentration <0.1ng/mL who 
do not receive antibiotics will be comparable, or noninferior, 
to those who do receive antibiotic therapy. This trial, which is 
in the protocol-development stage through the Vaccine and 
Treatment Evaluation Units (VTEUs), is intended to provide 
the data necessary to support an expanded indication-for-use 
statement.
ARLG LABORATORY CENTER AND STRAIN 
BIOREPOSITORIES [18]
The Laboratory Center (LC), described in detail along with 
their associated biorepositories elsewhere [18], is a resource 
developed by the ARLG to support ARLG-related projects, 
conduct laboratory-based research, and provide services and 
advice to the scientific community [38]. One of those services 
is the curation, maintenance, and dissemination of well-char-
acterized bacterial strains, including clinical isolates. Distinct 
from typical biobanking approaches, the ARLG maintains most 
of these strains in a decentralized manner. Housed at multiple 
locations, this strain library constitutes a virtual biorepository 
(VB). Strains in the VB are accompanied by data such as strain 
type, antimicrobial susceptibility testing results, genetic char-
acterization, and clinical information about the source of the 
isolate.
As the central point of contact, the LC reviews and approves 
strain requests, provides guidance during the selection process, 
and ships strains to requesting investigators. Requests are wel-
comed from the research community, clinical microbiologists, 
diagnostic companies, pharmaceutical companies, and other 
entities with relevant scientific interests [18].
ACCESS TO MATRIX AND SAMPLES
Diagnostics development often requires matrix (eg, blood, 
urine, cerebrospinal fluid, bronchoalveolar lavage fluid, rectal 
swab) to define parameters such as limits of detection, inter-
ference, and specimen stability, among others, through the cre-
ation of contrived (ie, spiked) samples. This can be critical to 
assay validation, particularly for rare analytes. In some cases, 
matrix is readily available (eg, urine). In other cases, it may be 
challenging to acquire (eg, cerebrospinal fluid, bronchoalve-
olar lavage fluid). The ARLG Laboratory and Leadership and 
Operations Centers together have developed protocols to pro-
vide such specimens to diagnostics developers using the ARLG’s 
network of trial sites and clinical partners. The CEP-VAP 
(Cepheid-Diagnostic for Ventilator Associated Pneumonia) 
project scavenged residual clinical bronchoalveolar lavage fluid 
samples that were used to develop pathogen detection assays 
for LRTI. The CEP-CRO (Cepheid-Diagnostic for Carbapenem 
Resistant Organisms) project scavenged clinical respiratory 
samples that were used to develop diagnostic tests to detect car-
bapenem-resistant gram-negative bacteria [42]. In this manner, 
the ARLG is able to help overcome a barrier in the diagnostic 
test development pathway.
CONCLUSIONS AND FUTURE DIRECTIONS
Recent technologic advances have spurred development of new 
tests that more rapidly and accurately detect and identify micro-
organisms as well as detect multiple pathogens and/or drug-re-
sistance mechanisms simultaneously. This armamentarium of 
new diagnostic tests has revolutionized the portfolio of clini-
cal microbiology laboratories, but clinical practices must also 
learn how best to use them. Advanced diagnostics have created 
a need for more implementation-science studies that explore 
how to operationalize and integrate these new tests into existing 
practice. This includes determining the ideal analyte panels for 
specific patient populations; the patient and clinical situation 
in which a test should be obtained; whether additional testing 
should be co-ordered or reflexively ordered; and how to report 
results such that they seamlessly integrate with clinical care 
decisions. This is especially important considering the large 
proliferation of novel diagnostic tests for routine clinical use.
Going forward, cost-effectiveness or clinical utility studies, 
akin to the study by Banerjee et  al [1], will help determine 
the optimal use of new technologies. The important outcome 
variables that future diagnostic studies should assess include 
impact on antimicrobial usage, time to effective or optimal 
therapy, patient length of stay, cost, mortality, and emer-
gence and spread of resistance. Multicenter studies will likely 
be required to have enough patients or clinical specimens to 
make statistically meaningful observations. The value of these 
tests in outpatient settings will likewise need to be defined. 
However, the costs to perform such studies can be substantial 
and must therefore be weighed against the available resources, 
low reimbursement for diagnostic testing, and anticipated clin-
ical impact. The ARLG, along with its academic and industry 
partners, have made progress in answering these challenges.
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